Your browser doesn't support javascript.
loading
Efficacy and safety of echinocandin monotherapy and combination therapy for immunocompromised patients with systemic candidiasis: A systematic review and meta-analysis.
Tang, Brenda Hui En; Bay, Jia Wei; Yeong, Foong May; Samuel, Miny.
Afiliação
  • Tang BHE; Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Dr, Singapore 117597, Republic of Singapore. Electronic address: brendatang@u.nus.edu.
  • Bay JW; Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Dr, Singapore 117597, Republic of Singapore.
  • Yeong FM; Department of Biochemistry, National University of Singapore, MD 7, 8 Medical Drive, Singapore 117596, Republic of Singapore.
  • Samuel M; Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Dr, Singapore 117597, Republic of Singapore.
J Mycol Med ; 33(2): 101362, 2023 May.
Article em En | MEDLINE | ID: mdl-36867970
ABSTRACT

BACKGROUND:

Systemic candidiasis is caused by Candida invading the bloodstream. The efficacy and safety of echinocandins in monotherapy and combination therapy regimes have not been adequately compared in immunocompromised patients with Candidiasis, and thus this systematic review aims to do so.

METHODS:

A protocol was prepared a priori. PubMed, Embase and Cochrane Library databases were searched systematically (from inception of each database to September 2022) to identify randomized controlled trials. Two reviewers performed screening, quality assessment of trials, and extracted data independently. Pairwise meta-analysis was performed using random-effects model to compare echinocandin monotherapy versus other antifungals. The primary outcomes of interest were treatment success and treatment-related adverse events.

RESULTS:

547 records (PubMed=310, EMBASE=210 and Cochrane Library=27) were reviewed. Following our screening criteria, six trials involving 177 patients were included. Risk of bias of four included studies had some concerns due to lack of a pre-specified analysis plan. Meta-analysis shows that echinocandin monotherapy does not have significantly higher rates of "treatment success" compared to other classes of antifungals (RR 1.12, 95%CI 0.80-1.56). However, echinocandins appeared to be significantly safer than other forms of antifungal therapy (RR 0.79, 95%CI 0.73-0.86).

CONCLUSION:

Our findings have shown that echinocandin monotherapy (micafungin, caspofungin) given intravenously are just as effective as other antifungals (amphotericin B, itraconazole) in the treatment of systemic candidiasis in immunocompromised patients. There appears to be similar benefits when using echinocandins compared to amphotericin B which has also been used as a broad-spectrum antifungal, while avoiding the severe adverse effects that amphotericin B causes, such as nephrotoxicity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Candidíase / Antifúngicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Candidíase / Antifúngicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article